BR112015002370B1 - Composição injetável compreendendo letrozol ou anastrozol - Google Patents

Composição injetável compreendendo letrozol ou anastrozol Download PDF

Info

Publication number
BR112015002370B1
BR112015002370B1 BR112015002370-3A BR112015002370A BR112015002370B1 BR 112015002370 B1 BR112015002370 B1 BR 112015002370B1 BR 112015002370 A BR112015002370 A BR 112015002370A BR 112015002370 B1 BR112015002370 B1 BR 112015002370B1
Authority
BR
Brazil
Prior art keywords
dmso
composition
aromatase inhibitor
inhibitor compound
pla
Prior art date
Application number
BR112015002370-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015002370A2 (pt
Inventor
Guillermo FRANCO RODRÍGUEZ
Ibon GUTIERRO ADURIZ
Original Assignee
Laboratorios Farmaceuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015002370(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmaceuticos Rovi, S.A. filed Critical Laboratorios Farmaceuticos Rovi, S.A.
Publication of BR112015002370A2 publication Critical patent/BR112015002370A2/pt
Publication of BR112015002370B1 publication Critical patent/BR112015002370B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015002370-3A 2012-08-03 2013-07-29 Composição injetável compreendendo letrozol ou anastrozol BR112015002370B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201231271A ES2390439B1 (es) 2012-08-03 2012-08-03 Composición inyectable
ESP201231271 2012-08-03
PCT/EP2013/065877 WO2014019972A1 (en) 2012-08-03 2013-07-29 Injectable compositions comprising letrozole or anastrozole

Publications (2)

Publication Number Publication Date
BR112015002370A2 BR112015002370A2 (pt) 2017-07-04
BR112015002370B1 true BR112015002370B1 (pt) 2023-04-25

Family

ID=47046938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002370-3A BR112015002370B1 (pt) 2012-08-03 2013-07-29 Composição injetável compreendendo letrozol ou anastrozol

Country Status (31)

Country Link
EP (1) EP2879661B1 (https=)
JP (1) JP6317348B2 (https=)
KR (1) KR101892109B1 (https=)
CN (1) CN104519870B (https=)
AU (1) AU2013298705B2 (https=)
BR (1) BR112015002370B1 (https=)
CA (1) CA2880347C (https=)
CL (1) CL2015000259A1 (https=)
CY (1) CY1125157T1 (https=)
DK (1) DK2879661T3 (https=)
EA (1) EA033316B1 (https=)
ES (2) ES2390439B1 (https=)
HR (1) HRP20220537T1 (https=)
HU (1) HUE058322T2 (https=)
IL (1) IL236981B (https=)
IN (1) IN2015DN01711A (https=)
LT (1) LT2879661T (https=)
MA (1) MA37870B1 (https=)
MX (1) MX362874B (https=)
MY (1) MY194726A (https=)
NZ (1) NZ705558A (https=)
PH (1) PH12015500231B1 (https=)
PL (1) PL2879661T3 (https=)
PT (1) PT2879661T (https=)
RS (1) RS63104B1 (https=)
SG (1) SG11201500793VA (https=)
SI (1) SI2879661T1 (https=)
SM (1) SMT202200127T1 (https=)
UA (1) UA113317C2 (https=)
WO (1) WO2014019972A1 (https=)
ZA (1) ZA201501426B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CA3157003A1 (en) * 2019-10-07 2021-04-15 Oak Crest Institute Of Science Orally implantable drug delivery device
KR102319352B1 (ko) 2021-02-03 2021-10-29 바이오메디팜 어업회사법인 주식회사 첨연어의 수컷화 비율을 높이는 비호르몬적 방법
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2025153747A1 (es) * 2024-01-17 2025-07-24 Laboratorios Farmacéuticos Rovi, S.A. Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB0517673D0 (en) 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
MX2009003737A (es) * 2006-10-05 2009-06-16 Panacea Biotec Ltd Composicion inyectable en deposito y su procedimiento de preparacion.
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
PT2394663T (pt) * 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物

Also Published As

Publication number Publication date
CY1125157T1 (el) 2024-02-16
EP2879661A1 (en) 2015-06-10
IN2015DN01711A (https=) 2015-05-22
UA113317C2 (xx) 2017-01-10
BR112015002370A2 (pt) 2017-07-04
DK2879661T3 (da) 2022-04-19
EA201500196A1 (ru) 2015-05-29
PH12015500231A1 (en) 2015-04-06
WO2014019972A1 (en) 2014-02-06
PT2879661T (pt) 2022-04-06
NZ705558A (en) 2018-02-23
IL236981B (en) 2021-12-01
SI2879661T1 (sl) 2022-07-29
JP2015523405A (ja) 2015-08-13
AU2013298705B2 (en) 2018-03-08
CN104519870A (zh) 2015-04-15
EP2879661B1 (en) 2022-01-26
MX2015001513A (es) 2015-04-08
PL2879661T3 (pl) 2022-05-16
ES2390439B1 (es) 2013-09-27
HUE058322T2 (hu) 2022-07-28
EA033316B1 (ru) 2019-09-30
ES2390439A1 (es) 2012-11-13
MY194726A (en) 2022-12-15
MA37870A1 (fr) 2016-04-29
JP6317348B2 (ja) 2018-04-25
LT2879661T (lt) 2022-04-11
RS63104B1 (sr) 2022-04-29
KR101892109B1 (ko) 2018-09-28
KR20150040337A (ko) 2015-04-14
HRP20220537T1 (hr) 2022-06-10
CN104519870B (zh) 2017-09-15
CL2015000259A1 (es) 2015-06-05
SG11201500793VA (en) 2015-02-27
AU2013298705A1 (en) 2015-03-12
ZA201501426B (en) 2016-01-27
MA37870B1 (fr) 2017-01-31
HK1204551A1 (en) 2015-11-27
ES2926715T3 (es) 2022-10-27
PH12015500231B1 (en) 2015-04-06
IL236981A0 (en) 2015-03-31
CA2880347C (en) 2021-05-04
CA2880347A1 (en) 2014-02-06
SMT202200127T1 (it) 2022-07-21
MX362874B (es) 2019-02-20

Similar Documents

Publication Publication Date Title
BR112015002370B1 (pt) Composição injetável compreendendo letrozol ou anastrozol
US11918682B2 (en) Injectable composition with aromatase inhibitor
BR112012030686B1 (pt) Composição de implante de formação in situ injetável de retardo de risperidona e kit farmacêutico
BRPI0909630B1 (pt) Composição em suspensão aquosa particularmente adequada para injeção dentro do olho
BR112014029208B1 (pt) composição para implante de paliperidona, método para fabricação da mesma e kit farmacêutico
EA023128B1 (ru) Способ получения инъекционной фармацевтической композиции с замедленным высвобождением ланреотида
JP7689499B2 (ja) 非プロトン性極性溶媒中の安定な治療用組成物およびその製造方法
BRPI0812250B1 (pt) Composição farmacêutica de liberação lenta de uma triptorelina agonista de lhrh feita de micropartículas e uso da mesma
Russo et al. Chitosan-clodronate nanoparticles loaded in poloxamer gel for intra-articular administration
RU2017108204A (ru) Композиции пролекарства арипипразола
Wang et al. An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade
JP2023538075A (ja) 長時間作用のインサイチュ形成／ゲル化組成物
HK1204551B (en) Injectable compositions
JP7767636B2 (ja) 疼痛治療用医薬組成物
BR112017006057B1 (pt) Composição farmacêutica à base de prostaglandina J2 incorporada em sistemas micelares baseados em poloxâmeros para potencialização das atividades analgésica e anti-inflamatória
HK40070081B (zh) 非质子极性溶剂中的稳定治疗组合物及其制造方法
Deadman Biopharmaceutical studies of slow release, subcutaneous polymeric drug delivery systems
BR122025015489A2 (pt) Métodos para produzir formulações terapêuticas estáveis em solventes apolares apróticos
BR112018005800B1 (pt) Método para estavelmente formular um peptídeo glucagon
BR112018005800A2 (en) methods for producing stable therapeutic formulations in aprotic nonpolar solvents

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2013, OBSERVADAS AS CONDICOES LEGAIS